LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Lilly's Loxo Presents Positive Phase I/II Data In MCL At ASH
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.